

## Brief History References

- Adams RD, Kakulas BA, Samaha FA. A myopathy with cellular inclusions. *Trans Am Neurol Assoc* 1965;90:213–6.
- Arahata, K. & Engel, A. G. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. *Ann. Neurol.* 16, 193–208 (1984).
- Askanas, V. & Engel, W. K. Inclusion-body myositis: a myodegenerative conformational disorder associated with A $\beta$ , protein misfolding, and proteasome inhibition. *Neurology* 66, S39–S48 (2006).
- Askanas, V., & Engel, W. K. (2007). Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-[beta], misfolded proteins, predisposing genes, and aging. *Current Opinion in Rheumatology*, 19(6), 550.
- Askanas, V., Engel, W. K. & Alvarez, R. B. Light and electron microscopic localization of  $\beta$ -amyloid protein in muscle biopsies of patients with inclusion-body myositis. *Am. J. Pathol.* 141, 31–36 (1992).
- Britson, K. A., Yang, S. Y., & Lloyd, T. E. (2018). New Developments in the Genetics of Inclusion Body Myositis. *Current Rheumatology Reports*, 20(5), 26. <https://doi.org/10.1007/s11926-018-0738-0>
- Britton, D., Karam, C., Schindler, J. S. (2018). Swallowing and Secretion Management in Neuromuscular Disease. *Clinics in Chest Medicine*, 39(2), 449-457. <https://doi.org/10.1016/j.ccm.2018.01.007>
- Chahin, N. & Engel, A. G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. *Neurology* 70, 418–424 (2008).
- Chou SM. Myxovirus-like structures in a case of human chronic polymyositis. *Science*, 1967;158:1453–5.
- Dalakas, M. C. (2006). Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies. *Nature Clinical Practice. Neurology*, 2(8), 437–447.
- Engel, A. G. & Arahata, K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. *Ann. Neurol.* 16, 209–215 (1984).
- Felice, K. J., Whitaker, C. H., Wu, Q., Larose, D. T., Shen, G., Metzger, A. L., & Barton, R. W. (2018). Sensitivity and clinical utility of the anti-cytosolic 5'-nucleotidase 1A (cN1A) antibody test in sporadic inclusion body myositis: report of 40 patients from a single neuromuscular center. *Neuromuscular Disorders*. <https://doi.org/10.1016/j.nmd.2018.06.005>

- Greenberg, S. A. (2019). Inclusion body myositis: Clinical features and pathogenesis. *Nature Reviews Rheumatology* 2019, 1. <https://doi.org/10.1038/s41584-019-0186-x>
- Greenberg, S. A., Pinkus, J. L., Amato, A. A., Kristensen, T. & Dorfman, D. M. Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. *Brain* 139, 1348–1360 (2016).
- Greenberg, S. A., Pinkus, J. L., Kong, S. W., Baecher-allan, C., Amato, A. A., & Dorfman, D. M. (2019). Highly differentiated cytotoxic T cells in inclusion body myositis. *Brain*, 1-15. <https://doi.org/10.1093/brain/awz214>
- Griggs, R. C., et al. Inclusion body myositis and myopathies. *Ann. Neurol.* 38, 705–713 (1995)
- Kagen, L. J. (2009). Inclusion Body Myositis. In L. J. Kagen (Ed.), *The Inflammatory Myopathies* (pp. 87–94). Totowa, NJ: Humana Press. [https://doi.org/10.1007/978-1-60327-827-0\\_5](https://doi.org/10.1007/978-1-60327-827-0_5)
- Larman, H., Salajegheh, M., Nazareno, R., Lam, T., Sauld, J., Steen, H., ... Greenberg, S. A. (2013). Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. *Annals of Neurology*, 73(3), 408–418. <https://doi.org/10.1002/ana.23840>
- Lilleker, J. B., Rietveld, A., Pye, S. R., Mariampillai, K., Benveniste, O., Peeters, M. T. J., ... Van Engelen, B. G. M. (2017). Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. *Annals of the Rheumatic Diseases*, 76(5), 862–868. <https://doi.org/10.1136/annrheumdis-2016-210282>
- Lotz, B. P., Engel, A. G., Nishino, H., Stevens, J. C., & Litchy, W. J. (1989). Inclusion body myositis. *Brain*, 112(3), 727–747. <https://doi.org/10.1093/brain/112.3.727>
- Mendell, J. R., Sahenk, Z., Gales, T. & Paul, L. (1991). Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments. *Arch. Neurol.* 48, 1229–1234 <https://doi.org/10.1001/archneur.1991.00530240033013>
- Needham, M., & Mastaglia, F. L. (2007). Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. *The Lancet Neurology*, 6(7), 620–631. [https://doi.org/10.1016/S1474-4422\(07\)70171-0](https://doi.org/10.1016/S1474-4422(07)70171-0)
- Oldfors, A., Larsson, N. G., Lindberg, C. & Holme, E. Mitochondrial DNA deletions in inclusion body myositis. *Brain* 116, 325–336 (1993).
- Pandya, J. M. et al. Expanded T cell receptor V $\beta$ -restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28 null T cells. *Arthritis Rheum.* 62, 3457–3466 (2010).
- Pluk, H., van Hoeve, B. J. a, van Dooren, S. H. J., Stammen-Vogelzangs, J., van der Heijden, A., Schelhaas, H. J., ... Pruijn, G. J. M. (2013). Autoantibodies to cytosolic 5'-nucleotidase 1A

in inclusion body myositis. *Annals of Neurology*, 73(3), 397–407.  
<https://doi.org/10.1002/ana.23822>

Pruitt, J. N., Showalter, C. J., & Engel, A. G. (1996). Sporadic inclusion body myositis: Counts of different types of abnormal fibers. *Annals of Neurology*, 39(1), 139–143.  
<https://doi.org/10.1002/ana.410390122>

Ramdharry, G., Morrow, J., Hudgens, S., Skorupinska, I., Gwathmey, K., Currence, M., ... Machado, P. M. (2019). Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis. *Muscle & Nerve*, 60(2), mus.26521.  
<https://doi.org/10.1002/mus.26521>

Rose, M. R. (2013). 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. *Neuromuscular Disorders*, 23(12), 1044–1055.  
<https://doi.org/10.1016/j.nmd.2013.08.007>

Rothwell, S. et al. Immune-array analysis in sporadic inclusion body myositis reveals HLA-DRB1 amino acid heterogeneity across the myositis spectrum. *Arthritis Rheumatol.* 69, 1090–1099 (2017).

Yunis EJ, Samaha FJ. (1971). Inclusion body myositis. *Lab Invest*; 25:240–8.